Orthocell partner Marine Biomedical wins FDA 510(k) clearance for PearlBone
Orthocell Limited (ASX: OCC) announced on 3 November 2026 that its strategic partner, Marine Biomedical Pty Ltd, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for PearlBone™, a marine-derived bone graft substitute.
The clearance enables PearlBone to be marketed in the United States for its cleared indications. The announcement describes it as advancing the product towards commercialisation in one of the world’s largest medical device markets.
Key facts on Orthocell’s position:
- Equity interest in Marine Biomedical: 12%
- Total investment: A$1.05 million
- First right of refusal over global distribution rights for PearlBone and future bone repair and regeneration products
John Van Der Wielen, Orthocell Chair
“Our investment in Marine Biomedical was made with a clear strategic objective: to secure exposure to an innovative bone regeneration technology with the potential to complement Orthocell’s established nerve and tendon repair portfolio.”
“Achieving FDA clearance is a significant step towards unlocking that opportunity…”
When big ASX news breaks, our subscribers know first
What PearlBone is and why bone regeneration matters
A bone graft substitute is a material used to support the repair and regeneration of bone. A 510(k) clearance is the FDA pathway that allows a device to be marketed in the United States.
PearlBone is described as a next-generation bone substitute developed using sustainably sourced pearl shell from Western Australia’s Kimberley region. It harnesses the natural properties of nacre, the biomineralised structure of pearl shell, to support bone repair and regeneration.
The product has potential applications across:
- Orthopaedic surgery
- Trauma surgery
- Reconstructive surgery
PearlBone is manufactured at Marine Biomedical’s purpose-built facility in Broome, Western Australia.
The clearance follows years of scientific development, preclinical evaluation, manufacturing validation and regulatory preparation. Orthocell describes it as an important step in de-risking the regulatory pathway and advancing the commercial opportunity.
Strategic value for Orthocell’s portfolio
Orthocell’s investment reflects its strategy to broaden its portfolio of biologically driven regenerative medicine products across bone, nerve and tendon repair. PearlBone extends that portfolio into bone, alongside its established nerve and tendon repair technologies.
| Tissue area | Product or technology | Status per source |
|---|---|---|
| Bone | PearlBone™ (Marine Biomedical) | U.S. FDA 510(k) clearance received; Orthocell holds a first right of refusal over global distribution rights |
| Nerve | Remplir™ | Recently gained clearance for use in the US |
| Tendon | SmrtGraft™ | Available in Australia under Special Access Scheme or participation in a clinical trial |
The clearance also creates the potential for Orthocell to leverage its established U.S. surgeon relationships, distributor network and commercial infrastructure to support the product’s introduction to market. This is subject to the exercise of its contractual rights and agreement of definitive commercial arrangements.
Remplir US sales have been building steadily, with October delivering the strongest month since launch as more surgeons, repeat users and active distributor reps came online.
Orthocell believes PearlBone has the potential to complement its existing portfolio, providing surgeons with an expanded suite of biologically advanced solutions for complex tissue repair and reconstruction.
What happens next for PearlBone
Two items shape the path from clearance to market:
- Commercial readiness: Marine Biomedical is progressing manufacturing readiness, market development and engagement with potential commercial and clinical partners ahead of the planned introduction of PearlBone into the U.S. market.
- Definitive commercial arrangements: Any Orthocell role in the product’s U.S. introduction is subject to the exercise of its contractual rights and agreement of definitive commercial arrangements.
For investors, the A$1.05 million investment gives Orthocell a 12% interest in a company that now holds FDA clearance for its lead bone graft product. The first right of refusal over global distribution rights is the key lever linking Orthocell to any future commercialisation.
For investors weighing the A$1.05 million stake, Orthocell’s own path to breakeven is relevant context, since management has said no additional capital is required and the company holds a multi-year cash runway.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to receive healthcare and other non-resource alerts the moment market-moving news breaks.